Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

EIF5A2 Antikörper (C-Term)

Der Kaninchen Polyklonal Anti-EIF5A2-Antikörper wurde für IHC validiert. Er ist geeignet, EIF5A2 in Proben von Human und Maus zu detektieren. Es sind 7+ Publikationen verfügbar.
Produktnummer ABIN966053

Kurzübersicht für EIF5A2 Antikörper (C-Term) (ABIN966053)

Target

Alle EIF5A2 Antikörper anzeigen
EIF5A2 (Eukaryotic Translation Initiation Factor 5A2 (EIF5A2))

Reaktivität

  • 32
  • 9
  • 5
  • 2
  • 2
  • 2
  • 2
  • 1
  • 1
  • 1
Human, Maus

Wirt

  • 30
  • 3
Kaninchen

Klonalität

  • 31
  • 2
Polyklonal

Konjugat

  • 24
  • 3
  • 2
  • 2
  • 1
  • 1
Dieser EIF5A2 Antikörper ist unkonjugiert

Applikation

  • 27
  • 18
  • 15
  • 6
  • 5
  • 2
  • 1
  • 1
Immunohistochemistry (IHC)
  • Bindungsspezifität

    • 8
    • 5
    • 3
    • 3
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    C-Term

    Immunogen

    Polyclonal antibody produced in rabbits immunizing with a synthetic peptide corresponding to C-terminal residues of human EIF5A2
  • Beschränkungen

    Nur für Forschungszwecke einsetzbar
  • Lagerung

    4 °C
  • Luo, Hua, Rao, Liao, Kung, Zeng, Guan, Chen, Xie: "Overexpression of EIF-5A2 predicts tumor recurrence and progression in pTa/pT1 urothelial carcinoma of the bladder." in: Cancer science, Vol. 100, Issue 5, pp. 896-902, (2009) (PubMed).

    Chen, Luo, Hua, Zhou, Lin, Kung, Zeng, Guan, Xie: "Overexpression of EIF-5A2 is an independent predictor of outcome in patients of urothelial carcinoma of the bladder treated with radical cystectomy." in: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, Vol. 18, Issue 2, pp. 400-8, (2009) (PubMed).

    Yang, Xie, Liu, Luo, Li, Hua, Wu, Kung, Zeng, Guan: "Expression and amplification of eIF-5A2 in human epithelial ovarian tumors and overexpression of EIF-5A2 is a new independent predictor of outcome in patients with ovarian carcinoma." in: Gynecologic oncology, Vol. 112, Issue 2, pp. 314-8, (2009) (PubMed).

    Xie, Ma, Pan, Wu, Liu, Wu, Kung, Guan: "Overexpression of EIF-5A2 is associated with metastasis of human colorectal carcinoma." in: Human pathology, Vol. 39, Issue 1, pp. 80-6, (2007) (PubMed).

    Ojima, Inoue, Miki, Mori, Kusunoki: "Effectiveness of gene expression profiling for response prediction of rectal cancer to preoperative radiotherapy." in: Journal of gastroenterology, Vol. 42, Issue 9, pp. 730-6, (2007) (PubMed).

    Andersen, Lam, Leung, Ong, Lyon, Lamond, Mann: "Nucleolar proteome dynamics." in: Nature, Vol. 433, Issue 7021, pp. 77-83, (2005) (PubMed).

    Guan, Fung, Ma, Lau, Tai, Xie, Zhang, Hu, Wu, Fang, Sham: "Oncogenic role of eIF-5A2 in the development of ovarian cancer." in: Cancer research, Vol. 64, Issue 12, pp. 4197-200, (2004) (PubMed).

  • Target

    EIF5A2 (Eukaryotic Translation Initiation Factor 5A2 (EIF5A2))

    Andere Bezeichnung

    EIF5A2

    Hintergrund

    EIF5A2 (Eukaryotic initiation factor 5A ) stimulates ribosomal peptidyltransferase activity, transport of HIV-1-mRNAs and binds exportins 1 and 4. Contains hypusine at lys 50. Human EIF5A1 and EIF5A2 encode two isoforms: eIF5AI and eIF5AII. Increased expression of EIF-5A2 in ovarian carcinoma may represent an acquired malignant phenotypic feature of tumor cells. Overexpression of EIF5A2 is an independent molecular marker for shortened survival time of patients with ovarian carcinoma.
Sie sind hier:
Chat with us!